Basic Stats
| LEI | 5299005C4HZL4UWROC14 |
| CIK | 1082554 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to United Therapeutics Corporation
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 2, 2025 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2025: United Therapeutic |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju |
|
| August 1, 2025 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 1, 2025: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that |
|
| August 1, 2025 |
Re: Collared Accelerated Share Repurchase Exhibit 10.1 Execution Version United Therapeutics Corporation 1000 Spring Street Silver Spring MD 20910 Attention: James Edgemond, Chief Financial Officer and Treasurer Re: Collared Accelerated Share Repurchase Ladies and Gentlemen: This master confirmation (this “Master Confirmation”), dated as of August 1, 2025 is intended to set forth certain terms and provisions of certain Transactions (each, |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 30, 2025 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results Record total revenue of $799 million, reflecting 12 percent growth over the second quarter of 2024 and 12 consecutive quarters of double-digit, year-over-year total revenue growth Share repurchase of up to $1 billion authorized by the Board of Directors, expiring March 31, 2026 T |
|
| July 30, 2025 |
Exhibit 10.3 EIGHTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Eighth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred |
|
| July 30, 2025 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0 |
|
| July 30, 2025 |
As filed with the Securities and Exchange Commission on July 30, 2025 As filed with the Securities and Exchange Commission on July 30, 2025 Registration No. |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| June 27, 2025 |
United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 26, 2025) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this “Plan”) is to advance the interests of United Therapeutics Corporation (the “Company”) by stimulating the efforts of employees, officers, non-employee directors and ot |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1000 Spring Street Silver Spring, MD 20910 (Addre |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number |
|
| April 30, 2025 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports First Quarter 2025 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 30, 2025: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year- |
|
| April 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Defin |
|
| April 28, 2025 |
Exhibit 10.1 Execution Version $2,500,000,000 CREDIT AGREEMENT dated as of April 25, 2025 by and among UNITED THERAPEUTICS CORPORATION, as Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, as Guarantors, THE LENDERS REFERRED TO HEREIN, as Lenders, BANK OF AMERICA, N.A., DNB MARKETS, INC., JPMORGAN CHASE BANK, N.A., PNC BANK, NATIONAL ASSOCIATION and U.S. BANK NATIONAL ASSOCIATION, as co |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| February 26, 2025 |
Exhibit 10.28 UNITED THERAPEUTICS CORPORATION GRANT NOTICE FOR 2015 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTIONS FOR NON-EMPLOYEE DIRECTORS FOR GOOD AND VALUABLE CONSIDERATION, United Therapeutics Corporation (the “Company”), hereby grants to Participant named below the nonqualified stock option (the “Option”) to purchase any part or all of the number of shares of its par value common stock (th |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 26, 2025 |
Exhibit 19 UNITED THERAPEUTICS CORPORATION AND SUBSIDIARIES STATEMENT OF COMPANY POLICY Securities Trades by Company Personnel United Therapeutics Corporation (the “Company”) has adopted this policy on insider trading (this “Policy”), which applies to each officer, director and employee of the Company or any of its subsidiaries, in order to reduce the risk of securities laws violations that could have severe civil and criminal consequences. |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu |
|
| February 26, 2025 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT IVIVA Medical, Inc., a Delaware corporation Lung Bioengineering Inc., a Delaware corporation Miromatrix Medical Inc., a Delaware corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales United Therapeutics Ireland Limited, a company incorporated under the laws of Irelan |
|
| February 26, 2025 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 26, 2025: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a r |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of United Therapeutics Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| January 13, 2025 |
Exhibit 99.1 United Therapeutics: Enabling Inspiration J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 13, 2025 2 INTRODUCTION Safe Harbor Statement MIROKIDNEY®, MIROLIVERELAP®, ORENITRAM®, REMODULIN®, TYVASO®, and TYVASO DPI® are registered trademarks of United Therapeutics Corporation and/or its subsidiaries. UHEART™, UKIDNEY™, ULOBE™, ULUNG™, and UTHYMOKIDNEY™ are trademarks of United Therapeutics Co |
|
| November 8, 2024 |
UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SC 13G/A Passive Investment SC 13G/A 1 tm2427864d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 6) United Therapeutics Corporation (Name of Issuer) Common Stoc |
|
| October 30, 2024 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Third Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., October 30, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 16, 2024 |
UTHR / United Therapeutics Corporation / STATE STREET CORP Passive Investment SC 13G 1 UnitedTherapeuticsCorp.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNITED THERAPEUTICS CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 91307C102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0 |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 31, 2024 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year- |
|
| July 31, 2024 |
Exhibit 10.2 SEVENTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Seventh Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referr |
|
| July 31, 2024 |
fth Amendment to Wholesale Product Purchase Agreement, dated as of Jun Exhibit 10.3 Twelfth Amendment To Wholesale Product Purchase Agreement THIS TWELFTH AMENDMENT TO WHOLESALE PRODUCT PURCHASE AGREEMENT (this “Twelfth Amendment”) is made as of the date the last Party executes this Twelfth Amendment (the “Amendment Effective Date”), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation ha |
|
| July 31, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| July 31, 2024 |
As filed with the Securities and Exchange Commission on July 31, 2024 As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. |
|
| June 27, 2024 |
Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 26, 2024) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this “Plan”) is to advance the interests of United Therapeutics Corporation (the “Company”) by stimulating the efforts of employees, officers, non-employee directors and ot |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| June 27, 2024 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 27, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the addition of former Minnesota Commissioner of Health Jan Malcolm to its Board of Directors. Ms. Malcolm was electe |
|
| June 10, 2024 |
UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: United Therapeutics Corp Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: May 31, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1000 Spring Street Silver Spring, MD 20910 (Addre |
|
| May 1, 2024 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports First Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 1, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-ove |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Defin |
|
| April 29, 2024 |
About United Therapeutics Our company was founded over 27 years ago with the challenge of finding a way to cure or treat a rare, life-threatening illness suffered by our CEO's daughter. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| March 25, 2024 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 25, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced |
|
| March 25, 2024 |
Exhibit 10.1 EXECUTION VERSION United Therapeutics Corporation 1000 Spring Street Silver Spring MD 20910 Attention: James Edgemond, Chief Financial Officer and Treasurer Re: Accelerated Share Repurchase Ladies and Gentlemen: This master confirmation (this “Master Confirmation”), dated as of March 25, 2024 is intended to set forth certain terms and provisions of certain Transactions (each, a “Trans |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| February 21, 2024 |
Exhibit 97 UNITED THERAPEUTICS CORPORATION CLAWBACK POLICY Adopted July 12, 2023 Recoupment of Incentive-Based Compensation It is the policy of United Therapeutics Corporation (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s consolidated financial statements (including any required accounting restatement to correct an error in previou |
|
| February 21, 2024 |
Exhibit 99.2 For Immediate Release United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., February 21, 2024 - United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement of litigation with the United States Food and Drug Administration (FDA). In the litigation, United Therapeutics alleges that |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu |
|
| February 21, 2024 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 United Therapeutics Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act): Common Stock, par value $0.01 per share (common stock). All references in this document to United Therapeutics, o |
|
| February 21, 2024 |
Exhibit 10.59 SIXTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Sixth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred |
|
| February 21, 2024 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 21, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a r |
|
| February 21, 2024 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT IVIVA Medical, Inc., a Delaware corporation Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Miromatrix Medical Inc., a Delaware corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales United Therapeutics Ir |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 21, 2024 |
Exhibit 10.52 Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Eleventh Amendment To Wholesale Product Purchase Agreement This Eleventh Amendment to Wholesale Product Purchase Agreement (this “Eleventh Amendment”) is made as of the date the last Party executes this Eleventh A |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 14, 2024 |
UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 13, 2024 |
UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02159-unitedtherapeuticsco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: United Therapeutics Corp Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 8, 2024 |
CELU / Celularity Inc. / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment SC 13G/A 1 tm245374d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 ) Celularity Inc. (Name of Issuer) Common Stock, $0.0001 par v |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* UNITED THERAPEUTICS Corp (Name of Issuer) Common Stock (Title of Class of Securities) 91307C102 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| December 22, 2023 |
MIRO / Miromatrix Medical Inc / UNITED THERAPEUTICS Corp - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Miromatrix Medical Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 60471P108 (CUSIP Number) John S. Hess, Jr., Esq. Executive Vice President and Deputy General Counsel United Therapeutics Corporation 1735 Connecticut Avenue, N.W |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju |
|
| December 13, 2023 |
Joint Press Release issued on December 13, 2023. Exhibit (a)(5)(E) For Immediate Release United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger SILVER SPRING, Md. |
|
| December 13, 2023 |
Gibson, Dunn & Crutcher LLP 1050 Connecticut Avenue, N.W. Washington, D.C. 20036-5306 Tel 202.955.8500 gibsondunn.com Stephen Glover Direct: +1 202.955.8593 Fax: +1 202.530.9598 [email protected] VIA EDGAR December 13, 2023 Brian Soares, Special Counsel Christina Chalk, Assistant Chief U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers & Acquisitions 10 |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par v |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par v |
|
| December 12, 2023 |
Joint Press Release issued on December 12, 2023. Exhibit (a)(5)(D) For Immediate Release United Therapeutics and Miromatrix Medical Announce Successful Tender Offer SILVER SPRING, Md. |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par v |
|
| December 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO-T (Rule 14d-100) Miromatrix Medical Inc. |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju |
|
| November 13, 2023 |
Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| November 13, 2023 |
Form of Notice of Guaranteed Delivery. Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY for Tender of Common Shares of MIROMATRIX MEDICAL INC. |
|
| November 13, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of MIROMATRIX MEDICAL INC. |
|
| November 13, 2023 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO-T (Rule 14d-100) Miromatrix Medical Inc. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per |
|
| November 13, 2023 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of MIROMATRIX MEDICAL INC. |
|
| November 13, 2023 |
Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of MIROMATRIX MEDICAL INC. |
|
| November 13, 2023 |
Offer to Purchase, dated November 13, 2023. TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of MIROMATRIX MEDICAL INC. |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 1, 2023 |
Exhibit 10.1 FIFTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Fifth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred t |
|
| November 1, 2023 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Third Quarter 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., November 1, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-o |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus Subsidiary Inc. a wholly owned subsidiary of United Therapeutics Corporation (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per |
|
| November 1, 2023 |
Exhibit 99.1 The following are excerpts from the transcript of United Therapeutics’ Q3 2023 earnings call held on November 1, 2023: Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer: Also, earlier this week, we announced an agreement to acquire publicly traded Miromatrix Medical, a company focused on ending the waiting list for organ transplantation. Miromatrix utilizes an organ ma |
|
| October 30, 2023 |
Exhibit 99.1 For Immediate Release United Therapeutics to Acquire Miromatrix Medical SILVER SPRING, Md., RESEARCH TRIANGLE PARK, N.C., and EDEN PRAIRIE, Minn., October 30, 2023 - United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus Subsidiary Inc. a wholly owned subsidiary of United Therapeutics Corporation (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per |
|
| October 30, 2023 |
Exhibit 99.1 United Therapeutics Investor FAQ Pending Acquisition of Miromatrix Medical, Inc. October 30, 2023 Why is United Therapeutics acquiring Miromatrix? Miromatrix is another shot on goal for our objective of creating an unlimited supply of tolerable, transplantable organs. This transaction would complement our capabilities in the organ manufacturing space and expand our early-stage pipelin |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus Subsidiary Inc. a wholly owned subsidiary of United Therapeutics Corporation (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per |
|
| August 2, 2023 |
Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 2, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-y |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 2, 2023 |
As filed with the Securities and Exchange Commission on August 2, 2023 As filed with the Securities and Exchange Commission on August 2, 2023 Registration No. |
|
| August 2, 2023 |
Exhibit 10.2 FOURTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Fourth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0 |
|
| August 2, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| July 24, 2023 |
Exhibit 99.1 For Immediate Release United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 24, 2023 - United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation Unit |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I. |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* UNITED THERAPEUTICS Corp (Name of Issuer) Common Stock (Title of Class of Securities) 91307C102 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| June 28, 2023 |
United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 26, 2023) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this “Plan”) is to advance the interests of United Therapeutics Corporation (the “Company”) by stimulating the efforts of employees, officers, non-employee directors and ot |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1040 Spring Street Silver Spring, MD 20910 (Addre |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 3, 2023 |
Exhibit 10.1 Tenth Amendment To Wholesale Product Purchase Agreement This Tenth Amendment to Wholesale Product Purchase Agreement (this “Tenth Amendment” is made as of the date the last Party executes this Tenth Amendment (the “Amendment Effective Date”), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation having offi |
|
| May 3, 2023 |
, between the Registrant and Accredo Health Group, Inc., incorporated by reference to Exhibit 10. Exhibit 10.2 THIRD AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Third Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred t |
|
| May 3, 2023 |
UNITED THERAPEUTICS CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 3, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number |
|
| April 28, 2023 |
.11 11 United Therapeutics C O R P O R A T I O N A Public Benefit Corporation Notice of Annual Meeting of Shareholders and Proxy Statement About United Therapeutics Our company was founded over 26 years ago with the challenge of finding a way to cure or treat a rare, life-threatening illness suffered by our CEO's daughter. That mission continues today, has grown to encompass a variety of rare dise |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 21, 2023 |
Exhibit 3.1 TENTH AMENDED AND RESTATED BYLAWS OF UNITED THERAPEUTICS CORPORATION (A PUBLIC BENEFIT CORPORATION) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of United Therapeutics Corporation, a public benefit corporation organized under the laws of the State of Delaware (the “Corporation”), shall be in the State of Delaware at such location and with such registered agen |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| February 22, 2023 |
Exhibit 10.37 UNITED THERAPEUTICS CORPORATION GRANT NOTICE FOR 2015 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTIONS FOR EMPLOYEES (PERFORMANCE VESTING) FOR GOOD AND VALUABLE CONSIDERATION, United Therapeutics Corporation (the “Company”), hereby grants to Participant named below the nonqualified stock option (the “Option”) to purchase any part or all of the number of shares of its par value common |
|
| February 22, 2023 |
Exhibit 10.38 UNITED THERAPEUTICS CORPORATION GRANT NOTICE FOR 2015 STOCK INCENTIVE PLAN RESTRICTED STOCK UNITS FOR EMPLOYEES (PERFORMANCE VESTING) FOR GOOD AND VALUABLE CONSIDERATION, United Therapeutics Corporation (the “Company”), hereby grants to Participant named below the restricted stock units (the “Award”) with respect to the number of shares of its par value common stock (the “Shares”), t |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 22, 2023 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales United Therapeutics Ireland Limited, a company incorporated under the laws of Ireland Unither Biotech Inc., a Cana |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu |
|
| February 22, 2023 |
UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 22, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues ros |
|
| February 14, 2023 |
SC 13G/A 1 p23-0578sc13ga.htm UNITED THERAPEUTICS CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of T |
|
| February 9, 2023 |
UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02126-unitedtherapeuticsco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: United Therapeutics Corp. Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* United Therapeutics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 91307C102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 6, 2023 |
CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 3, 2023 |
CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment SC 13G/A 1 tm234873d1sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1) Celularity Operations Inc. (Name of Issuer) Common Stock, $0.0 |
|
| February 3, 2023 |
CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 2, 2023 |
UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juri |
|
| January 9, 2023 |
EX-99.1 2 tm232645d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UTHR: A Public Benefit Corporation | January 2023 | 1 United Therapeutics: Enabling Inspiration J.P. Morgan 41 st Annual Healthcare Conference UTHR: A Public Benefit Corporation | January 2023 | 2 Safe Harbor Statement This presentation contains forward - looking statements which represent United Therapeutics’ expectations or beliefs regardi |
|
| November 2, 2022 |
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Third Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., November 2, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 3 |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 11, 2022 |
Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON 2 STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., October 11, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer J |
|
| September 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juri |
|
| September 1, 2022 |
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation Exhibit 99.1 United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., August 31, 2022 ? United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics? U.S. pate |
|
| August 9, 2022 |
M e d i c i n e s F o r L i f e ® 1040 Spring Street Silver Spring, MD 20910 tel 301.608.9292 fax 301.608.9291 August 9, 2022 SUBMITTED VIA EDGAR Division of Corporate Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Christie Wong and Daniel Gordon Re: United Therapeutics Corporation Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 24 |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 3, 2022 |
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Second Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 3, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 202 |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0 |
|
| August 3, 2022 |
Exhibit 10.3 SECOND AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Second Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred |
|
| August 3, 2022 |
EX-FILING FEES 4 tm2222193d1ex-filingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr |
|
| August 3, 2022 |
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| June 28, 2022 |
United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 27, 2022) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this ?Plan?) is to advance the interests of United Therapeutics Corporation (the ?Company?) by stimulating the efforts of employees, officers, non-employee directors and ot |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1040 Spring Street Silver Spring, MD 20910 (Addre |
|
| May 24, 2022 |
Exhibit 99.1 United Therapeutics Announces FDA Approval of Tyvaso DPI? First approval of a dry powder inhaler for treatment of PAH and PH-ILD DPI device represents a convenient option for administration of treprostinil therapy Commercial launch activities underway; patient availability expected in June 2022 SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., May 24, 2022 ? United Therapeutics Co |
|
| May 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdi |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number |
|
| May 4, 2022 |
United Therapeutics Corporation Reports First Quarter 2022 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports First Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 4, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. |
|
| May 4, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This First Amendment to Specialty Pharmacy Network Agreement (this ?Amendment?) is made as of the date the last Party executes this Amendment (the ?Amendment Effective Date?), by and between Accredo Health Group, Inc. (?Specialty Pharmacy?), and United Therapeutics Corporation (?UT?). Specialty Pharmacy and UT are each referred t |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 29, 2022 | ||
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| April 1, 2022 |
? Exhibit 10.1 ? Execution Version ? ? ? $2,000,000,000 ? CREDIT AGREEMENT ? dated as of March 31, 2022 ? by and among ? UNITED THERAPEUTICS CORPORATION, as Borrower, ? CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, as Guarantors, ? THE LENDERS REFERRED TO HEREIN, as Lenders, ? BANK OF AMERICA, N.A., DNB CAPITAL LLC, MUFG Bank, Ltd., and PNC BANK, NATIONAL ASSOCIATION, as co-Syndication Agents |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu |
|
| February 24, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 United Therapeutics Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act): Common Stock, par value $0.01 per share (common stock). All references in this document to United Therapeutics, o |
|
| February 24, 2022 |
Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results Double-digit percentage revenue and patient count growth in full-year 2021 Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 Major amendment to Tyvaso DPI? NDA pushes FDA deci |
|
| February 24, 2022 |
Exhibit 10.57 Ninth Amendment To Wholesale Product Purchase Agreement This Ninth Amendment to Wholesale Product Purchase Agreement (this ?Ninth Amendment? is made as of the date the last Party executes this Ninth Amendment (the ?Amendment Effective Date?), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation having off |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 24, 2022 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales Unither Biotech Inc., a Canadian company Unither Bioelectronics, Inc., a Canadian company Unither Pharma, LLC, a D |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 10, 2022 |
UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: United Therapeutics Corp. Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 4, 2022 |
UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| February 4, 2022 |
CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju |
|
| November 3, 2021 |
United Therapeutics Corporation Reports Third Quarter 2021 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Third Quarter 2021 Financial Results SILVER SPRING, MD. and RESEARCH TRIANGLE PARK, N.C., November 3, 2021: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announce |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num |
|
| October 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| October 18, 2021 |
Exhibit 99.1 For Immediate Release United Therapeutics Provides an Update on the Progress of the Tyvaso DPI? New Drug Application Draft label contains both PAH and PH-ILD indications; no contraindications and no boxed warning Complete response cites an open inspection issue at a third-party analytical testing facility; no other deficiencies cited Approval and launch expected in summer 2022 or earl |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer J |
|
| October 1, 2021 |
Exhibit 10.1 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?), dated as of , is made by and between UNITED THERAPEUTICS CORPORATION, a Delaware public benefit corporation (the ?Company?), and (the ?Indemnitee?), an ?agent? (as hereinafter defined) of the Company. RECITALS A. The Company recognizes that competent and experienced persons are increasingly reluctant |
|
| October 1, 2021 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF UNITED THERAPEUTICS CORPORATION (A PUBLIC BENEFIT CORPORATION) It is hereby certified that: 1. The present name of the corporation (hereinafter called the ?corporation?) is United Therapeutics Corporation. The name under which the corporation was originally incorporated was Lung Rx, Inc.; and the date of filing the original certificate of incorp |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 19, 2021 | ||
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 4, 2021 |
Form S-8 (No. 333-258434) filed with the Securities and Exchange Commission on August 4, 2021 As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. |
|
| August 4, 2021 |
Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Second Quarter 2021 Financial Results Tyvaso? (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year Tyvaso DPI? NDA under review with FDA action expected in October 2021 SILVER SPRING, MD |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0 |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| June 25, 2021 |
United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 25, 2021) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this ?Plan?) is to advance the interests of United Therapeutics Corporation (the ?Company?) by stimulating the efforts of employees, officers, non-employee directors and ot |
|
| June 23, 2021 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| June 16, 2021 |
Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF TYVASO DPI? NEW DRUG APPLICATION FOR PRIORITY REVIEW FDA action expected in October 2021 SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., Wednesday, June 16, 2021 ? United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the Ne |
|
| June 7, 2021 |
UNITED THERAPEUTICS PURSUES NEW CLAIMS FOR TRADE SECRET MISAPPROPRIATION AGAINST LIQUIDIA Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS PURSUES NEW CLAIMS FOR TRADE SECRET MISAPPROPRIATION AGAINST LIQUIDIA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Monday, June 7, 2021: United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary of Liquidia Cor |
|
| June 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdi |
|
| June 3, 2021 |
Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS First pivotal study of Tyvaso? (treprostinil) Inhalation Solution outside pulmonary hypertension SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Thursday, June 3, 2021: United Therapeutics Corporation (Nasdaq: UTHR) announced t |
|
| June 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdi |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1040 Spring Street Silver Spring, MD 20910 (Addre |
|
| May 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 5, 2021 |
Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso? (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI? New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETO |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2021 |
- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2021 | ||
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 19, 2021 |
Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES SUBMISSION OF TYVASO DPI™ NEW DRUG APPLICATION TO FDA NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indications Priority review voucher applied to the NDA submission SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Monday, April 19, 2021: United T |
|
| April 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris |
|
| April 1, 2021 |
Exhibit 99.1 For Immediate Release United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need FDA approval based on data from the INCREASE cli |
|
| April 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| March 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd |
|
| March 1, 2021 |
SC 13G/A 1 tm218268d1sc13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. ) United Therapeutics Corporation (Name of Issuer) Common |
|
| February 24, 2021 |
Description of Securities Registered under Section 12 of the Exchange Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 United Therapeutics Corporation (?United Therapeutics?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our Common Stock, par value $0.01 per share (our ?common stock?). DESCRIPTION OF COMMON |
|
| February 24, 2021 |
UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Silver Spring, MD and Research Triangle Park, NC, February 24, 2021: United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-263 |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 24, 2021 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Revivicor, Inc., a Delaware corporation SteadyMed Ltd., an Israeli company SteadyMed Therapeutics, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales Unither Biotech Inc., a Ca |
|
| February 12, 2021 |
United Therapeutics Corporation SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| February 10, 2021 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: United Therapeutics Corp. Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 10, 2021 |
UNITED THERAPEUTICS ANNOUNCES COMMERCIAL LAUNCH OF THE REMUNITY® PUMP FOR REMODULIN® Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES COMMERCIAL LAUNCH OF THE REMUNITY® PUMP FOR REMODULIN® SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Wednesday, February 10, 2021: United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity® Pump for Remodulin® for patients with pulmonary arterial hypertensio |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 5, 2021 |
Exhibit 3.1 NINTH AMENDED AND RESTATED BYLAWS OF UNITED THERAPEUTICS CORPORATION ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of United Therapeutics Corporation (the “Corporation”) shall be in the State of Delaware at such location and with such registered agent in charge thereof as may be established by the Board of Directors from time to time. Section 1.2. Other Office |
|
| January 28, 2021 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| January 28, 2021 |
Exhibit 99.1 UNITED THERAPEUTICS ANNOUNCES BREEZE STUDY OF INVESTIGATIONAL TYVASO DPI™ MEETS PRIMARY OBJECTIVE Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution Tyvaso DPI NDA filing antici |
|
| January 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| January 13, 2021 |
Exhibit 99.1 For Immediate Release United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments Company to host a webcast detaili |
|
| January 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| December 28, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju |
|
| December 28, 2020 |
Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE PRIORITY REVIEW VOUCHER Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Monday, December 28, 2020: United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV |
|
| December 23, 2020 |
1735 Connecticut Ave., NW Washington, DC 20009 tel 202.483.7000 fax 202.483.4005 December 23, 2020 SUBMITTED VIA EDGAR Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Attention: Dorrie Yale Suzanne Hayes Li Xiao Brian Cascio Re: United Therapeutics Corporation Form 10-K for the Fiscal Year Ended December 31, 2020 Filed |
|
| December 9, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur |
|
| December 9, 2020 |
Exhibit 99.1 For Immediate Release For Further Information Contact: Dewey Steadman at (202) 919-4097 Email: [email protected] United Therapeutics Receives FDA Orphan Drug Designation for TREPROSTINIL for the Treatment of Idiopathic Pulmonary Fibrosis Phase 3 TETON study planned in 2021 for Tyvaso® in patients with idiopathic pulmonary fibrosis SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Wedn |
